NASDAQ:PYPD PolyPid (PYPD) Stock Price, News & Analysis → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Free PYPD Stock Alerts $5.00 +0.30 (+6.38%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$5.00▼$5.5050-Day Range$4.64▼$6.9952-Week Range$3.57▼$14.70Volume4,573 shsAverage Volume7,489 shsMarket Capitalization$24 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get PolyPid alerts: Email Address Ad Insiders ExposedThis consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here. About PolyPid Stock (NASDAQ:PYPD)PolyPid Ltd., a clinical-stage pharmaceutical company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which helps in the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.Read More PYPD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PYPD Stock News HeadlinesFebruary 28, 2024 | globenewswire.comPolyPid to Participate in Barclays 26th Annual Global Healthcare ConferenceFebruary 19, 2024 | finance.yahoo.comPolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?March 29, 2024 | WealthPress (Ad)A lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. February 15, 2024 | finance.yahoo.comPolyPid Ltd. (NASDAQ:PYPD) Q4 2023 Earnings Call TranscriptFebruary 14, 2024 | markets.businessinsider.comBuy Rating for PolyPid Amid Positive D-PLEX100 Trial Prospects and Strategic Market PositioningFebruary 14, 2024 | finanznachrichten.dePolyPid Ltd.: PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 14, 2024 | finance.yahoo.comPolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 14, 2024 | globenewswire.comPolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 29, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. February 12, 2024 | finanznachrichten.dePolyPid Ltd.: PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 TrialFebruary 12, 2024 | finance.yahoo.comPolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 TrialJanuary 31, 2024 | finance.yahoo.comPolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024January 5, 2024 | msn.comWhy Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day SessionJanuary 5, 2024 | msn.comCyclacel Pharmaceuticals, Angiodynamic among healthcare moversJanuary 4, 2024 | uk.finance.yahoo.comPolyPid Ltd. (PYPD)January 4, 2024 | msn.comPolyPid looks to raise $16.2M through private placementJanuary 4, 2024 | finance.yahoo.comPolyPid Announces Private Placement for $16 Million in Gross ProceedsNovember 12, 2023 | finance.yahoo.comPolyPid Ltd. (NASDAQ:PYPD) Q3 2023 Earnings Call TranscriptNovember 12, 2023 | investing.comEarnings call: PolyPid's Q3 2023 financial results show decreased expenses and progress in SHIELD II trialNovember 8, 2023 | finance.yahoo.comPolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsNovember 7, 2023 | benzinga.comPolyPid's Earnings: A PreviewNovember 7, 2023 | finance.yahoo.comPolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of DirectorsNovember 1, 2023 | finance.yahoo.comPolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023October 24, 2023 | msn.comBarclays Maintains Polypid (PYPD) Equal-Weight RecommendationOctober 19, 2023 | finance.yahoo.comPolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price RuleOctober 13, 2023 | msn.comHC Wainwright & Co. Initiates Coverage of Polypid (PYPD) with Buy RecommendationOctober 12, 2023 | markets.businessinsider.comPromising Clinical Trials and Innovative PLEX Technology Drive Analyst’s Buy Rating for PolyPid Ltd.See More Headlines Receive PYPD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PolyPid and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today3/29/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:PYPD CUSIPN/A CIK1611842 Webwww.polypid.com Phone972-74-719-5700FaxN/AEmployees57Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($19.6823) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-450.37% Return on Assets-101.27% Debt Debt-to-Equity Ratio2.17 Current Ratio0.83 Quick Ratio0.83 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.27) per share Price / Book-3.94Miscellaneous Outstanding Shares4,800,000Free Float3,612,000Market Cap$24 million OptionableOptionable Beta1.43 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMs. Dikla Czaczkes Akselbrad (Age 51)CEO & Director Comp: $422.33kMs. Dalit Hazan (Age 53)Executive Vice President of R&D and Clinical & Regulatory Affairs Comp: $312.25kMr. Ori Warshavsky (Age 46)Chief Operating Officer - US Comp: $335.52kMr. Jonny Missulawin (Age 37)Chief Financial Officer Ms. Maria RubinVice President of OperationsMr. Tal VilnaiGeneral Counsel & Corporate SecretaryMs. Rivi Lev-ariVice President of Human ResourceDr. Jean-Marc Hagai Pharm.D.Chief Commercial OfficerMore ExecutivesKey CompetitorsPlus TherapeuticsNASDAQ:PSTVNeuroMetrixNASDAQ:NUROVapothermNYSE:VAPOGlucoTrackNASDAQ:GCTKVivos TherapeuticsNASDAQ:VVOSView All Competitors PYPD Stock Analysis - Frequently Asked Questions Should I buy or sell PolyPid stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PolyPid in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PYPD shares. View PYPD analyst ratings or view top-rated stocks. How have PYPD shares performed in 2024? PolyPid's stock was trading at $3.80 at the beginning of the year. Since then, PYPD shares have increased by 31.6% and is now trading at $5.00. View the best growth stocks for 2024 here. When is PolyPid's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our PYPD earnings forecast. How were PolyPid's earnings last quarter? PolyPid Ltd. (NASDAQ:PYPD) released its earnings results on Wednesday, February, 14th. The company reported ($3.97) EPS for the quarter, missing the consensus estimate of ($2.17) by $1.80. When did PolyPid's stock split? PolyPid's stock reverse split before market open on Thursday, September 21st 2023. The 1-30 reverse split was announced on Wednesday, September 20th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of PolyPid own? Based on aggregate information from My MarketBeat watchlists, some companies that other PolyPid investors own include Advanced Micro Devices (AMD), Moderna (MRNA), Sorrento Therapeutics (SRNE), Trevena (TRVN), Cardinal Health (CAH), Genocea Biosciences (GNCA), LightPath Technologies (LPTH), Stride (LRN) and Livongo Health (LVGO). When did PolyPid IPO? PolyPid (PYPD) raised $50 million in an initial public offering on Friday, June 26th 2020. The company issued 3,100,000 shares at a price of $15.00-$17.00 per share. Barclays and BMO Capital Markets acted as the underwriters for the IPO and Raymond James, National Securities Corporation, Oddo BHF and A.G.P. were co-managers. Who are PolyPid's major shareholders? PolyPid's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of PolyPid? Shares of PYPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PYPD) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchAI healthcare stock poised for 36,996% growth?Behind the MarketsMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PolyPid Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.